Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema

Phase 3

Completed

Conditions: Diabetic Macular Edema

Interventions: Drug: 0.3 mg intravitreal ranibizumab
Drug: 2.0 mg intravitreal aflibercept
Drug: 1.25 mg intravitreal bevacizumab

Registration Number: NCT01627249

Lead Sponsor: Jaeb Center for Health Research

Brief Summary: Although multiple studies have suggested that treatment with ranibizumab is safe and efficacious and superior to focal/grid laser alone for patients with center-involved diabetic macular edema (DME), there may be barriers in place to widespread adoption of ranibizumab use given its high cost per dose and the need for multiple treatments over time. Prioritizing resources from a public health policy perspective could be easier if more precise estimates regarding the risks and benefits of other anti-vascular endothelial growth factor (anti-VEGF) therapies were available, especially when the difference in costs could be billions of dollars over just a few years. Thus, there is a clear rationale at this time to explore potential anti-VEGF alternatives to ranibizumab that might prove to be as or more efficacious, might deliver equally lasting or longer-lasting treatment effects, and cost substantially less. Of the potentially available alternative anti-VEGF agents for this trial, bevacizumab and aflibercept are the best candidates for a direct comparison study. Bevacizumab shares the most similar molecular structure, costs far less, and is widely available. Furthermore, there is already preliminary evidence to suggest that it may be efficacious in the treatment of DME and it is already being widely used for this indication. Although aflibercept has a similar cost per unit dose to ranibizumab, it has the potential to decrease treatment burden and associated cost. If results from a comparative trial demonstrate improved efficacy or suggest similar efficacy of bevacizumab or aflibercept over ranibizumab, this information might give clinicians scientific rationale to substitute either one of these drugs for ranibizumab in the treatment of DME, and might thereby have substantial implications for public policy in terms of future estimates of health care dollars and possibly number of treatments necessary for anti-VEGF treatment of diabetic macular disease.

Because of its availability and lower cost, bevacizumab is already currently in widespread clinical use for treatment of DME despite the lack of FDA approval for this indication. Thus, a clinical trial that suggested whether bevacizumab could be used as a safe and efficacious alternative to ranibizumab could substantially impact nationwide practice patterns for treatment of DME by either validating the current use of bevacizumab or by demonstrating improved outcomes with ranibizumab or aflibercept treatment for DME.

Study Objective The primary objective of the proposed research is to compare the efficacy and safety of (1) intravitreal aflibercept, (2) intravitreal bevacizumab, and (3) intravitreal ranibizumab when given to treat central-involved DME in eyes with visual acuity of 20/32 to 20/320.

Detailed Description: A five year follow-up visit is being conducted to gather information on long term outcomes

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 660

Inclusion Criteria

Age ≥ 18 years
Individuals <18 years old are not being included because DME is so rare in this age group that the diagnosis of DME may be questionable.
Diagnosis of diabetes mellitus (type 1 or type 2)
Any one of the following will be considered to be sufficient evidence that diabetes is present:
Current regular use of insulin for the treatment of diabetes
Current regular use of oral anti-hyperglycemia agents for the treatment of diabetes
Documented diabetes by American Diabetes Association and/or World Health Organization criteria (see Procedures Manual for definitions)
At least one eye meets the following study eye criteria:
- Best corrected Electronic-Early Treatment Diabetic Retinopathy Study visual acuity letter score ≤ 78 (i.e., 20/32 or worse) and ≥ 24 (i.e., 20/320 or better) within eight days of randomization.
- On clinical exam, definite retinal thickening due to diabetic macular edema involving the center of the macula.
- Diabetic macular edema present on optical coherence tomography (OCT) (central subfield thickness on OCT >250 µm on Zeiss Stratus or the equivalent on spectral domain OCTs based on gender specific cutoffs), within eight days of randomization.
- Investigator must verify accuracy of OCT scan by ensuring it is centered and of adequate quality (for Zeiss Stratus, standard deviation of center point thickness should be ≤ 10% of the center point thickness and signal strength should be ≥ 6)
- Media clarity, pupillary dilation, and individual cooperation sufficient for adequate fundus photographs
Able and willing to provide informed consent.

Exclusion Criteria

Significant renal disease, defined as a history of chronic renal failure requiring dialysis or kidney transplant.
A condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure, cardiovascular disease, and glycemic control).

•Individuals in poor glycemic control who, within the last four months, initiated intensive insulin treatment (a pump or multiple daily injections) or plan to do so in the next four months should not be enrolled.
Participation in an investigational trial within 30 days of randomization that involved treatment with any drug that has not received regulatory approval for the indication being studied at the time of study entry.

• Note: study participants cannot receive another investigational drug while participating in the study.
Known allergy to any component of the study drug.
Blood pressure > 180/110 (systolic above 180 OR diastolic above 110).

• If blood pressure is brought below 180/110 by anti-hypertensive treatment, individual can become eligible.
Myocardial infarction, other acute cardiac event requiring hospitalization, stroke, transient ischemic attack, or treatment for acute congestive heart failure within 4 months prior to randomization.
Systemic anti-VEGF or pro-VEGF treatment within four months prior to randomization or anticipated use during the study.

• These drugs cannot be used during the study.
For women of child-bearing potential: pregnant or lactating or intending to become pregnant within the next 24 months.
Women who are potential study participants should be questioned about the potential for pregnancy. Investigator judgment is used to determine when a pregnancy test is needed.
Individual is expecting to move out of the area of the clinical center to an area not covered by another clinical center during the first 12 months of the study.

The following exclusions apply to the study eye only (i.e., they may be present for the nonstudy eye):

Macular edema is considered to be due to a cause other than diabetic macular edema.
An eye should not be considered eligible if: (1) the macular edema is considered to be related to ocular surgery such as cataract extraction or (2) clinical exam and/or OCT suggest that vitreoretinal interface abnormalities (e.g., a taut posterior hyaloid or epiretinal membrane) are the primary cause of the macular edema.
An ocular condition is present such that, in the opinion of the investigator, visual acuity loss would not improve from resolution of macular edema (e.g., foveal atrophy, pigment abnormalities, dense subfoveal hard exudates, nonretinal condition).
An ocular condition is present (other than diabetes) that, in the opinion of the investigator, might affect macular edema or alter visual acuity during the course of the study (e.g., vein occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, etc.).
Substantial cataract that, in the opinion of the investigator, is likely to be decreasing visual acuity by three lines or more (i.e., cataract would be reducing acuity to 20/40 or worse if eye was otherwise normal).
History of an anti-VEGF treatment for DME in the past 12 months or history of any other treatment for DME at any time in the past four months (such as focal/grid macular photocoagulation, intravitreal or peribulbar corticosteroids).
Enrollment will be limited to a maximum of 25% of the planned sample size with any history of anti-VEGF treatment for DME. Once this number of eyes has been enrolled, any history of anti-VEGF treatment for DME will be an exclusion criterion.
History of pan-retinal photocoagulation within four months prior to randomization or anticipated need for pan-retinal photocoagulation in the six months following randomization.
History of anti-VEGF treatment for a disease other than DME in the past 12 months.
History of major ocular surgery (including vitrectomy, cataract extraction, scleral buckle, any intraocular surgery, etc.) within prior four months or anticipated within the next six months following randomization.
History of YAG capsulotomy performed within two months prior to randomization.
Aphakia.
Exam evidence of external ocular infection, including conjunctivitis, chalazion, or significant blepharitis.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Ranibizumab	0.3 mg intravitreal ranibizumab	-
Aflibercept	2.0 mg intravitreal aflibercept	-
Bevacizumab	1.25 mg intravitreal bevacizumab	-

Primary Outcome Measures

Name	Time	Method
Change in Electronic Early Treatment Diabetic Retinopathy Study Visual Acuity Letter Score From Baseline to 1-year: Baseline Visual Acuity Letter Score 78-69	Baseline to 1-year	Visual Acuity was measured with the Electronic Early Treatment Study (E-ETDRS) visual acuity test. Unit of measure is based on the E-ETDRS letter score scale, 0-97, where 0 = worst and 97 = best.
Overall Change in Electronic Early Treatment Diabetic Retinopathy Study Visual Acuity Letter Score From Baseline to 1-year	Baseline to 1-year	Visual Acuity was measured with the Electronic Early Treatment Study (E-ETDRS) visual acuity test. Unit of measure is based on the E-ETDRS letter score scale, 0-97, where 0 = worst and 97 = best.
Change in Electronic Early Treatment Diabetic Retinopathy Study Visual Acuity Letter Score From Baseline to 1-year: Baseline Visual Acuity Letter Score <69	Baseline to 1-year	Visual Acuity was measured with the Electronic Early Treatment Study (E-ETDRS) visual acuity test. Unit of measure is based on the E-ETDRS letter score scale, 0-97, where 0 = worst and 97 = best.

Secondary Outcome Measures

Name	Time	Method
Overall Change in Optical Coherence Tomography Central Subfield Thickness	baseline to 1-year	All baseline and 1-year optical coherence tomography (OCT) scans were graded by Duke Reading Center. In addition, a random sample of OCT images from other visits and images for which the investigator believed central grading was needed also were graded by Duke Reading Center. Baseline CSF values were converted from the thickness value measured on a Spectralis or Cirrus OCT machine to a Stratus equivalent value for 583 scans. One-year CSF values were converted from a thickness value measured on a Spectralis or Cirrus OCT machine to a Stratus equivalent value for 604 scans. When calculating change in CSF thickness, measurements taken on the same machine at both visits were not converted, since the conversion equation slope is nearly 1 and the constant difference does not affect the change calculation. Therefore, change in CSF thickness was calculated after converting either the baseline and/or follow-up thickness value from Spectralis or Cirrus to a Stratus equivalent value in 26 eyes.
Change in Optical Coherence Tomography Central Subfield Thickness: Baseline Visual Acuity Letter Score 78-69	baseline to 1-year	All baseline and 1-year optical coherence tomography (OCT) scans were graded by Duke Reading Center. In addition, a random sample of OCT images from other visits and images for which the investigator believed central grading was needed also were graded by Duke Reading Center. Baseline CSF values were converted from the thickness value measured on a Spectralis or Cirrus OCT machine to a Stratus equivalent value for 583 scans. One-year CSF values were converted from a thickness value measured on a Spectralis or Cirrus OCT machine to a Stratus equivalent value for 604 scans. When calculating change in CSF thickness, measurements taken on the same machine at both visits were not converted, since the conversion equation slope is nearly 1 and the constant difference does not affect the change calculation. Therefore, change in CSF thickness was calculated after converting either the baseline and/or follow-up thickness value from Spectralis or Cirrus to a Stratus equivalent value in 26 eyes.
Total Number of Laser Treatments	between 24 weeks and 1 year	Only includes participants that completed the 1 year visit.
Change in Optical Coherence Tomography Central Subfield Thickness: Baseline Visual Acuity Letter Score <69	baseline to 1-year	All baseline and 1-year optical coherence tomography (OCT) scans were graded by Duke Reading Center. In addition, a random sample of OCT images from other visits and images for which the investigator believed central grading was needed also were graded by Duke Reading Center. Baseline CSF values were converted from the thickness value measured on a Spectralis or Cirrus OCT machine to a Stratus equivalent value for 583 scans. One-year CSF values were converted from a thickness value measured on a Spectralis or Cirrus OCT machine to a Stratus equivalent value for 604 scans. When calculating change in CSF thickness, measurements taken on the same machine at both visits were not converted, since the conversion equation slope is nearly 1 and the constant difference does not affect the change calculation. Therefore, change in CSF thickness was calculated after converting either the baseline and/or follow-up thickness value from Spectralis or Cirrus to a Stratus equivalent value in 26 eyes.
Overall Change in Retinal Volume	Baseline to 1-year	Baseline volume values were converted from the thickness value measured on a Spectralis or Cirrus OCT machine to a Stratus equivalent value for 459 scans. One-year volume values were converted from a thickness value measured on a Spectralis or Cirrus OCT machine to a Stratus equivalent value for 472 scans. When calculating change in volume, measurements taken on the same machine at both visits were not converted, because the conversion equation slope is nearly 1 and the constant difference does not affect the change calculation. Therefore, change in volume was calculated after converting either the baseline and/or follow-up value from Spectralis or Cirrus to a Stratus equivalent value in 17 eyes.
Total Number of Injections Prior to 1 Year	Baseline to 1-year	Only includes participants that completed the 1 year visit
Eyes Receiving 1 or More Alternative Treatments for DME Other Than Laser	Baseline to 1-year

Trial Locations

Locations (90): Loma Linda University Health Care, Dept. of Ophthalmology
🇺🇸
Loma Linda, California, United States
Retina-Vitreous Associates Medical Group
🇺🇸
Beverly Hills, California, United States
Southern California Desert Retina Consultants, MC
🇺🇸
Palm Desert, California, United States
Bay Area Retina Associates
🇺🇸
Walnut Creek, California, United States
California Retina Consultants
🇺🇸
Santa Barbara, California, United States
New England Retina Associates
🇺🇸
Norwich, Connecticut, United States
National Ophthalmic Research Institute
🇺🇸
Fort Myers, Florida, United States
Retina Group of Florida
🇺🇸
Fort Lauderdale, Florida, United States
Gulf Coast Retina Center
🇺🇸
Clearwater, Florida, United States
Central Florida Retina Institute
🇺🇸
Lakeland, Florida, United States
Ocala Eye Retina Consultants
🇺🇸
Ocala, Florida, United States
Fort Lauderdale Eye Institute
🇺🇸
Plantation, Florida, United States
Sarasota Retina Institute
🇺🇸
Sarasota, Florida, United States
Southeast Retina Center, P.C.
🇺🇸
Augusta, Georgia, United States
John-Kenyon American Eye Institute
🇺🇸
New Albany, Indiana, United States
Medical Associates Clinic, P.C.
🇺🇸
Dubuque, Iowa, United States
Wolfe Eye Clinic
🇺🇸
West Des Moines, Iowa, United States
Retina Associates, P.A.
🇺🇸
Shawnee Mission, Kansas, United States
Vitreo-Retinal Associates, PC
🇺🇸
Worcester, Massachusetts, United States
Retina Vitrous Center
🇺🇸
Grand Blanc, Michigan, United States
Vitreo-Retinal Associates
🇺🇸
Grand Rapids, Michigan, United States
Barnes Retina Institute
🇺🇸
Saint Louis, Missouri, United States
Eyesight Ophthalmic Services, PA
🇺🇸
Portsmouth, New Hampshire, United States
The Institute of Ophthalmology and Visual Science (IOVS)
🇺🇸
Newark, New Jersey, United States
The New York Eye and Ear Infirmary/Faculty Eye Practice
🇺🇸
New York, New York, United States
MaculaCare
🇺🇸
New York, New York, United States
Mount Sinai School of Medicine, Dept. of Ophthalmology
🇺🇸
New York, New York, United States
Retina-Vitreous Surgeons of Central New York, PC
🇺🇸
Syracuse, New York, United States
Western Carolina Retinal Associates, PA
🇺🇸
Asheville, North Carolina, United States
Charlotte Eye, Ear, Nose and Throat Assoc., PA
🇺🇸
Charlotte, North Carolina, United States
Retina Associates of Cleveland, Inc.
🇺🇸
Beachwood, Ohio, United States
Retina Vitreous Center
🇺🇸
Edmond, Oklahoma, United States
Family Eye Group
🇺🇸
Lancaster, Pennsylvania, United States
Palmetto Retina Center
🇺🇸
Columbia, South Carolina, United States
Carolina Retina Center
🇺🇸
Columbia, South Carolina, United States
Southeastern Retina Associates, PC
🇺🇸
Kingsport, Tennessee, United States
Southeastern Retina Associates, P.C.
🇺🇸
Knoxville, Tennessee, United States
Southwest Retina Specialists
🇺🇸
Amarillo, Texas, United States
Texas Retina Associates
🇺🇸
Lubbock, Texas, United States
Valley Retina Institute
🇺🇸
McAllen, Texas, United States
Virginia Retina Center
🇺🇸
Leesburg, Virginia, United States
Spokane Eye Clinic
🇺🇸
Spokane, Washington, United States
Emory Eye Center
🇺🇸
Atlanta, Georgia, United States
University of Illinois at Chicago Medical Center
🇺🇸
Chicago, Illinois, United States
Georgia Retina, P.C.
🇺🇸
Atlanta, Georgia, United States
Thomas Eye Group
🇺🇸
Atlanta, Georgia, United States
Northwestern Medical Faculty Foundation
🇺🇸
Chicago, Illinois, United States
NorthShore University HealthSystem
🇺🇸
Glenview, Illinois, United States
Wilmer Eye Institute at Johns Hopkins
🇺🇸
Baltimore, Maryland, United States
Paducah Retinal Center
🇺🇸
Paducah, Kentucky, United States
University of Pennsylvania Scheie Eye Institute
🇺🇸
Philadelphia, Pennsylvania, United States
Elman Retina Group, P.A.
🇺🇸
Baltimore, Maryland, United States
OSU Eye Physicians and Surgeons, LLC.
🇺🇸
Columbus, Ohio, United States
Retina Vitrous Consultants
🇺🇸
Pittsburgh, Pennsylvania, United States
Ophthalmic Consultants of Boston
🇺🇸
Boston, Massachusetts, United States
Joslin Diabetes Center
🇺🇸
Boston, Massachusetts, United States
Case Western Reserve University
🇺🇸
Cleveland, Ohio, United States
Retina and Vitreous of Texas
🇺🇸
Houston, Texas, United States
Baylor Eye Physicians and Surgeons
🇺🇸
Houston, Texas, United States
Retina Consultants of Houston, PA
🇺🇸
Houston, Texas, United States
University of Washington Medical Center
🇺🇸
Seattle, Washington, United States
Raj K. Maturi, M.D., P.C.
🇺🇸
Indianapolis, Indiana, United States
Retina Center, PA
🇺🇸
Minneapolis, Minnesota, United States
Retinal Consultants of San Antonio
🇺🇸
San Antonio, Texas, United States
Retina Associates of Utah, P.C.
🇺🇸
Salt Lake City, Utah, United States
Henry Ford Health System, Dept of Ophthalmology and Eye Care Services
🇺🇸
Detroit, Michigan, United States
Retina Northwest, PC
🇺🇸
Portland, Oregon, United States
Mayo Clinic Department of Ophthalmology
🇺🇸
Rochester, Minnesota, United States
Dean A. McGee Eye Institute
🇺🇸
Oklahoma City, Oklahoma, United States
Casey Eye Institute
🇺🇸
Portland, Oregon, United States
Retina Associates of Florida, P.A.
🇺🇸
Tampa, Florida, United States
Medical College of Wiconsin
🇺🇸
Milwaukee, Wisconsin, United States
Magruder Eye Institute
🇺🇸
Orlando, Florida, United States
Storm Eye Institute, Medical University of South Carolina
🇺🇸
Charleston, South Carolina, United States
University of North Carolina
🇺🇸
Chapel Hill, North Carolina, United States
Wake Forest University Eye Center
🇺🇸
Winston-Salem, North Carolina, United States
Retina Consultants of Hawaii, Inc.
🇺🇸
Honolulu, Hawaii, United States
Retina and Vitreous Associates of Kentucky
🇺🇸
Lexington, Kentucky, United States
Eye Associates of New Mexico
🇺🇸
Albuquerque, New Mexico, United States
University of New Mexico Health Sciences Center
🇺🇸
Albuquerque, New Mexico, United States
Retina Associates of Western New York
🇺🇸
Rochester, New York, United States
University of Rochester
🇺🇸
Rochester, New York, United States
Austin Retina Associates
🇺🇸
Austin, Texas, United States
Retina Research Center
🇺🇸
Austin, Texas, United States
Retina Institute of Virginia
🇺🇸
Richmond, Virginia, United States
University of Wisconsin-Madison, Dept of Ophthalmology/Retina Service
🇺🇸
Madison, Wisconsin, United States
Retina Associates
🇺🇸
Tucson, Arizona, United States
Retinal Consultants of Southern California Medical Group, Inc.
🇺🇸
Westlake Village, California, United States
Retina Specialists of Michigan
🇺🇸
Grand Rapids, Michigan, United States
Montefiore Medical Center
🇺🇸
Bronx, New York, United States